Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma

This publication has 47 references indexed in Scilit:

• RECIST 1.1 in NSCLC Patients With EGFR Mutations Treated With EGFR Tyrosine Kinase Inhibitors: Comparison With RECIST 1.0
  American Journal of Roentgenology, 2013
• Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
  Clinical Cancer Research, 2013
• Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors
  Lung Cancer, 2013
• The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
  Cancer Discovery, 2012
• Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation
  Clinical Cancer Research, 2011
• A method and server for predicting damaging missense mutations
  Nature Methods, 2010
• New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
  European Journal of Cancer, 2009
• MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
  Proceedings of the National Academy of Sciences, 2007
• TP53Mutations and Survival in Squamous-Cell Carcinoma of the Head and Neck
  New England Journal of Medicine, 2007
• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
  PLOS Medicine, 2005